These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12563)

  • 21. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology.
    Hamilton TC; Parkes MW
    Arzneimittelforschung; 1977 Jul; 27(7):1410-7. PubMed ID: 20114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading.
    Fromm MF; Darbar D; Dell'Orto S; Roden DM
    J Pharmacol Exp Ther; 1999 Jul; 290(1):253-8. PubMed ID: 10381784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of atenolol in clinically normal cats.
    Quiñones M; Dyer DC; Ware WA; Mehvar R
    Am J Vet Res; 1996 Jul; 57(7):1050-3. PubMed ID: 8807020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].
    Bianchetti G; Gomeni R; Kilborn JR; Morselli PL; Taylor EA; Warrington SJ
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P-404P. PubMed ID: 41556
    [No Abstract]   [Full Text] [Related]  

  • 26. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
    Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
    Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of renal failure on the hepatic clearance of bufuralol in man.
    Balant L; Francis RJ; Tozer TN; Marmy A; Tschopp JM; Fabre J
    J Pharmacokinet Biopharm; 1980 Oct; 8(5):421-38. PubMed ID: 6114166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bufuralol, a new beta-adrenoceptor blocking agent.
    Fothergill GA; Francis RJ; Hamilton TC; Osbond JM; Parkes MW
    Experientia; 1975 Nov; 31(11):1322-3. PubMed ID: 1287
    [No Abstract]   [Full Text] [Related]  

  • 33. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
    Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
    Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacological studies with tolamolol in man.
    Faulkner JK; Stopher DA; Walden R
    Br J Clin Pharmacol; 1975 Oct; 2(5):423-8. PubMed ID: 786354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.
    Francis RJ; East PB; Larman J
    Eur J Clin Pharmacol; 1982; 23(6):529-33. PubMed ID: 6130953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].
    Femmer K; Klemm W; Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673-5. PubMed ID: 694
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties.
    Frishman W
    Am Heart J; 1979 May; 97(5):663-70. PubMed ID: 34989
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of the new beta-adrenoceptor blocker SL 75212 in man after repeated oral administration [proceedings].
    Bianchetti G; Blatrix C; Gomeni R; Kilborn JR; Larribaud J; Lücker PW; Morselli PL; Thébault JJ; Trocherie S
    Br J Clin Pharmacol; 1979 Oct; 8(4):408P. PubMed ID: 41560
    [No Abstract]   [Full Text] [Related]  

  • 39. The pharmacokinetic properties of beta adrenoceptor blocking drugs.
    Gugler R
    Arch Int Pharmacodyn Ther; 1980; Suppl():27-31. PubMed ID: 6106455
    [No Abstract]   [Full Text] [Related]  

  • 40. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.
    Dayer P; Balant L; Küpfer A; Courvoisier F; Fabre J
    Eur J Clin Pharmacol; 1983; 24(6):797-9. PubMed ID: 6136413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.